This page contains a Flash digital edition of a book.
show preview | Market He attributes a key element in the company’s


international success to its strategy of retaining its focus on high technology manufacturing and offering the same level of quality and machine technology to its customers worldwide. Over the past two years the company has invested


Above: Engel’s HQ at Schwert- berg in Austria – the company posted record results last year


maintain the market at around this level over the coming decade.


Neumann said he believes Engel, which posted its


best ever result of €950m for its last financial year (the 12 months to the end of March), is well positioned for further growth in a market that is increasingly moving away from low technology moulding equipment. The company claims a 14% share of the world injection machinery market in value terms. Neumann said he estimates that Engel now holds a 30% market share in Europe and an 18% share in America. He also claims a 10% share of the high end Asian market (which he defines as the sector serviced by European and Japanese technology). “Engel has gained market share in all markets. From


2004 to 2012 our biggest jump was in Asia but that was from a very small level. In Europe we probably cannot grow much more from a 30% market share. In America there is a lot more competition from Asia but we have also grown our share there,” he said.


Figure 1: Injection moulding machinery sales by region, 1990-2020 (units)


Region Europe


America (North and South) China


Asia (excluding China) RoW Total


Source: Engel


Figure 2: Injection machinery market data by region, 2012 Europe 11,334


Total market (units) Market value (€ 000s)


Average machine value (€)* Source: Engel


40


America 7,861


1,336,000 117,875


INJECTION WORLD | September 2013


896,000 113,980


Asia 65,954


3,193,000 48,412


(*Average machine value by calculation)


1990 9,500 7,500 4,000 1,200 1,500


23,700 2011


12,340 8,030


50,000 21,450 2,500


94,320


2012 2020 11,300 7,900


45,000 21,000 3,400


88,600


14,000 7,000


35,000 24,000 4,000


84,000


close to €70m in its global manufacturing operations. The bulk of this has gone into Europe, which accounted for 65% of the company’s sales last year. This included expansion of its main machine manufacturing plants at Schwertberg and St Valentin in Austria, introduction of flow line production at its robot plant at Dietach (also in Austria) and expansion of its automation unit at Hagen in Germany. It also established a new Technical Centre at Stuttgart in Germany, its most important national market generating some 20% of its total sales.


Investing in Asia Engel generated a new sales record of €145m for the Asian region last year, the bulk of which came from China. Neumann said the company is the only western injection machinery manufacturer to operate two production plants in Asia. It continues to invest in the operations, which already account for around 75% of its sales in the region. The company has invested €12m in its plant at Shanghai in China to double its production capacity for large injection machines. A further €8m has gone into its operation at Pyeongtaek City in Korea to lift its capacity for smaller moulding machines to 1,200 machines a year. Neumann told Injection World magazine that Engel also benefited from its decision to adopt a market- focused approach to the market. This has seen the company develop specialised machines such as the e-Cap closure manufacturing system and has helped it develop a considerable presence in the packaging market. Engel claims 12% of its European machine sales now go to customers in this sector. Neumann believes further manufacturing capacity


investments, together with the continued focus on innovative manufacturing technologies, will ensure the company continues on its growth path. He expects Engel to post a 5% increase in annual sales for each of the next three years. “Our aim is to be the best at creating customer benefit,” he said. “Being near to our customers is key to this. On the one hand, this means increasing our global production capacity and expanding our sales and service structures continuously, and on the other hand it means consistently aligning our products and technologies to the individual requirements of country- specific markets and target sectors.” ❙ www.engelglobal.com


www.injectionworld.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70